Inaktiver Wert

Occlutech Holding AG Aktie

Aktien

Dauer

Zeitraum

Stil

Occlutech Holding AG setzt seine Fortschritte in der US FDA-Studie OCCLUFLEX fort – Erster Patient in Europa rekrutiert	31.01.23	CI
Occlutech Holding AG ernennt Jozef Bartunek zum neuen Chief Medical Officer	01.11.22	CI
Occlutech Holding AG ernennt Jose De La Cortina zum Chief Commercial Officer	06.09.22	CI

Occlutech Holding AG Continues its Progress in US FDA Study OCCLUFLEX – Enrolls First Patient in Europe	31.01.23
Occlutech Holding AG Appoints Jozef Bartunek as New Chief Medical Officer	01.11.22
Occlutech Holding AG Appoints Jose De La Cortina as Chief Commercial Officer	06.09.22
Occlutech Holding AG announced that it has received SEK 450 million in funding from AP Fonden 4, Carnegie Investment Bank AB	21.12.21
Occlutech Holding AG has withdrawn its IPO in the amount of SEK 963.8035 million.	28.09.21

Sektor